Kindred Biosciences Inc. (KIN) 6.77 $KIN
The New Baupost Biotech Picks
Matthew Finston - at Seeking Alpha - Mon Dec 15, 8:53AM CST
BIIB: 340.89 (+5.13), FWP: 20.13 (-0.17), MRK: 57.46 (+0.25), AVEO: 0.82 (+0.01), IDIX: 24.50 (+0.05), ATRA: 28.00 (+0.41), THRX: 14.55 (+0.22), TBPH: 14.84 (+0.20), PRTK: 37.70 (+1.30), KIN: 6.77 (+0.11), KERX: 14.00 (+0.20)
Kindred Biosciences (KIN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 7:33AM CST
Kindred Biosciences (KIN) in the Medical – Biomed/Gene space is seeing solid earnings estimate revisions, and is a great company from a Zacks Industry Rank perspective.
KIN: 6.77 (+0.11)
Kindred Biosciences, Inc. (KIN) in Focus: Stock Soars 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 8:18AM CST
Kindred Biosciences, Inc. (KIN) was a big mover last session, as the company saw its shares rise by nearly 11% on the day.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), KIN: 6.77 (+0.11), AFFX: 9.80 (+0.05)
Kindred Bio exits atopic dermatitis, shares drop
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 6:24AM CST
KIN: 6.77 (+0.11)
KindredBio Announces Update on AtoKin and Atopic Dermatitis Program
PR Newswire - Wed Dec 03, 3:01PM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has re-assessed its atopic dermatitis program and the atopic dermatitis market and has decided to discontinue its AtoKin study in favor of directing resources toward other programs in its portfolio.
KIN: 6.77 (+0.11)
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST
OCN: 14.88 (-0.14), KOS: 8.31 (-0.06), KIN: 6.77 (+0.11), VSAT: 63.75 (-0.20), RFMD: 16.59 (+0.29), EBAY: 57.10 (-0.12), TQNT: 27.72 (+0.50), IDIX: 24.50 (+0.05), SEMI: 18.72 (-0.39), VRTV: 50.15 (+0.09), THRX: 14.55 (+0.22), TBPH: 14.84 (+0.20), IMOS: 23.04 (+0.18), ELOS: 9.53 (-0.02), MU: 34.91 (-0.06), AR: 42.50 (-0.64), NCQ: 0.55 (unch), PBF: 25.99 (+0.15), LNG: 71.64 (-0.12), ATRA: 28.00 (+0.41), KERX: 14.00 (+0.20), NG: 2.82 (+0.10), AOI: 1.58 (unch), FWP: 20.13 (-0.17), BYD: 12.28 (+0.14), ALDW: 12.24 (-0.12), SUNE: 19.50 (+0.01), MRK: 57.46 (+0.25), AVEO: 0.82 (+0.01), AIG: 56.28 (-0.16)
KindredBio to Present at Jefferies 2014 Global London Healthcare Conference
PR Newswire - Mon Nov 17, 7:30AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will be presenting at the 2014 Jefferies Global Healthcare Conference in London on Thursday, November 20, 2014 at 5:00 PM GMT.
KIN: 6.77 (+0.11)
Kindred Biosciences' (KIN) CEO Richard Chin on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 7:43PM CST
KIN: 6.77 (+0.11)
Kindred Biosciences beats by $0.14
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:21PM CST
KIN: 6.77 (+0.11)
Kindred Biosciences Announces Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 13, 3:01PM CST
Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended September 30, 2014.
KIN: 6.77 (+0.11)
Kindred Bio to Announce Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 8:02AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its third quarter 2014 financial results on November 13, 2014 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day.
KIN: 6.77 (+0.11)
5 Stocks With Big Insider Buying
at The Street - Wed Oct 01, 11:43AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
CLR: 38.78 (-1.48), CONN: 18.23 (+1.23), AEO: 13.53 (+0.02), AGCO: 45.46 (-0.81), KIN: 6.77 (+0.11)
Kinark Outdoor Centre Hosts 10th Annual Haliburton-Muskoka-Kawartha Children's Water Festival
CNW Group - Mon Sep 29, 12:58PM CDT
On Monday, September 29(th) and Tuesday, September 30(th), the 10(th) Annual Haliburton-Muskoka-Kawartha (HMK) Children's Water Festival will be held at the Kinark Outdoor Centre (KOC) in Minden, Ontario. The festival, a project of the charitable organization Friends of Ecological and Environmental Learning (FEEL), is a free educational event, which complements the Ontario curriculum, offered to students in Grades 2 to 6 across the Trillium Lakelands District School Board. "The KOC is a natural landscape, central to the Trillium Lakelands District School Board, making the event accessible to children across the Board," explains Irene Heaven, Festival Coordinator.
KIN: 6.77 (+0.11)
5 Stocks Insiders Love Right Now
at The Street - Wed Sep 03, 12:32PM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
SCCO: 27.90 (+0.16), BXS: 22.50 (-0.02), JBHT: 84.91 (-0.02), CSLT: 12.14 (+0.30), KIN: 6.77 (+0.11)
Kindred Biosciences Falls on Disappointing CereKin Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 8:22AM CDT
Shares of Kindred Biosciences, Inc. (KIN) plunged 28.2% as a pivotal field study on its pipeline candidate CereKin (interleukin-1 inhibitor) failed to meet the primary endpoint.
CBPO: 64.79 (-0.59), CBM: 21.62 (+0.37), AMGN: 160.67 (+3.15), KIN: 6.77 (+0.11)
Kindred Biosciences (KIN) in Focus: Stock Tanks 28.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 7:43AM CDT
Kindred Biosciences has seen negative earnings estimate revisions for the current year along with a significant decline in its share price for the past month
CBPO: 64.79 (-0.59), CBM: 21.62 (+0.37), EPZM: 17.71 (+0.01), KIN: 6.77 (+0.11)
Why Kindred Biosciences (KIN) Stock Is Plummeting Today
at The Street - Thu Aug 21, 12:07PM CDT
Kindred Biosciences (KIN) plummeted Thursday after the company announced one of its three lead drug candidates failed to reach its goal in a trial.
KIN: 6.77 (+0.11)
Stock Futures In Positive Mood; Bon Ton Stores Skid Lower
at Investor's Business Daily - Thu Aug 21, 8:09AM CDT
Stock futures stuck to their early gains ahead of Thursday's open, as Europe's markets traded higher and weekly jobless claims data was positive. Dow futures rose 31. 9 points above fair market value. Nasdaq 100 futures notched up 3.6 points and S&P...
MGNX: 33.00 (+0.34), DLTR: 69.86 (-0.20), BONT: 7.52 (+0.40), KIN: 6.77 (+0.11)
KINDRED BIOSCIENCES
at Investor's Business Daily - Wed Aug 20, 5:56PM CDT
KINDRED BIOSCIENCES (KIN) said its CereKin drug to treat pain and inflammation related to osteoarthritis in dogs did not meet goals in a clinical trial. Shares fell 37%.
KIN: 6.77 (+0.11)
Kindred Biosciences Announces Top-Line Results from Pivotal Study of CereKin in Dogs with Osteoarthritis
PR Newswire - Wed Aug 20, 3:01PM CDT
Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that its pivotal field study (KB010) of CereKin, an interleukin-1 inhibitor for the control of pain and inflammation associated with osteoarthritis in dogs, did not meet its primary endpoint. The randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of two doses of CereKin (5 mg/kg and 20 mg/kg).
KIN: 6.77 (+0.11)
The New Baupost Biotech Picks
Matthew Finston - at Seeking Alpha - Mon Dec 15, 8:53AM CST
BIIB: 340.89 (+5.13), FWP: 20.13 (-0.17), MRK: 57.46 (+0.25), AVEO: 0.82 (+0.01), IDIX: 24.50 (+0.05), ATRA: 28.00 (+0.41), THRX: 14.55 (+0.22), TBPH: 14.84 (+0.20), PRTK: 37.70 (+1.30), KIN: 6.77 (+0.11), KERX: 14.00 (+0.20)
Kindred Biosciences (KIN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 7:33AM CST
Kindred Biosciences (KIN) in the Medical – Biomed/Gene space is seeing solid earnings estimate revisions, and is a great company from a Zacks Industry Rank perspective.
KIN: 6.77 (+0.11)
Kindred Biosciences, Inc. (KIN) in Focus: Stock Soars 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 8:18AM CST
Kindred Biosciences, Inc. (KIN) was a big mover last session, as the company saw its shares rise by nearly 11% on the day.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), KIN: 6.77 (+0.11), AFFX: 9.80 (+0.05)
Kindred Bio exits atopic dermatitis, shares drop
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 6:24AM CST
KIN: 6.77 (+0.11)
KindredBio Announces Update on AtoKin and Atopic Dermatitis Program
PR Newswire - Wed Dec 03, 3:01PM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has re-assessed its atopic dermatitis program and the atopic dermatitis market and has decided to discontinue its AtoKin study in favor of directing resources toward other programs in its portfolio.
KIN: 6.77 (+0.11)
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST
OCN: 14.88 (-0.14), KOS: 8.31 (-0.06), KIN: 6.77 (+0.11), VSAT: 63.75 (-0.20), RFMD: 16.59 (+0.29), EBAY: 57.10 (-0.12), TQNT: 27.72 (+0.50), IDIX: 24.50 (+0.05), SEMI: 18.72 (-0.39), VRTV: 50.15 (+0.09), THRX: 14.55 (+0.22), TBPH: 14.84 (+0.20), IMOS: 23.04 (+0.18), ELOS: 9.53 (-0.02), MU: 34.91 (-0.06), AR: 42.50 (-0.64), NCQ: 0.55 (unch), PBF: 25.99 (+0.15), LNG: 71.64 (-0.12), ATRA: 28.00 (+0.41), KERX: 14.00 (+0.20), NG: 2.82 (+0.10), AOI: 1.58 (unch), FWP: 20.13 (-0.17), BYD: 12.28 (+0.14), ALDW: 12.24 (-0.12), SUNE: 19.50 (+0.01), MRK: 57.46 (+0.25), AVEO: 0.82 (+0.01), AIG: 56.28 (-0.16)
KindredBio to Present at Jefferies 2014 Global London Healthcare Conference
PR Newswire - Mon Nov 17, 7:30AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will be presenting at the 2014 Jefferies Global Healthcare Conference in London on Thursday, November 20, 2014 at 5:00 PM GMT.
KIN: 6.77 (+0.11)
Kindred Biosciences' (KIN) CEO Richard Chin on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 7:43PM CST
KIN: 6.77 (+0.11)
Kindred Biosciences beats by $0.14
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:21PM CST
KIN: 6.77 (+0.11)
Kindred Biosciences Announces Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 13, 3:01PM CST
Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended September 30, 2014.
KIN: 6.77 (+0.11)
Kindred Bio to Announce Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 06, 8:02AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its third quarter 2014 financial results on November 13, 2014 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day.
KIN: 6.77 (+0.11)
5 Stocks With Big Insider Buying
at The Street - Wed Oct 01, 11:43AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
CLR: 38.78 (-1.48), CONN: 18.23 (+1.23), AEO: 13.53 (+0.02), AGCO: 45.46 (-0.81), KIN: 6.77 (+0.11)
Kinark Outdoor Centre Hosts 10th Annual Haliburton-Muskoka-Kawartha Children's Water Festival
CNW Group - Mon Sep 29, 12:58PM CDT
On Monday, September 29(th) and Tuesday, September 30(th), the 10(th) Annual Haliburton-Muskoka-Kawartha (HMK) Children's Water Festival will be held at the Kinark Outdoor Centre (KOC) in Minden, Ontario. The festival, a project of the charitable organization Friends of Ecological and Environmental Learning (FEEL), is a free educational event, which complements the Ontario curriculum, offered to students in Grades 2 to 6 across the Trillium Lakelands District School Board. "The KOC is a natural landscape, central to the Trillium Lakelands District School Board, making the event accessible to children across the Board," explains Irene Heaven, Festival Coordinator.
KIN: 6.77 (+0.11)
5 Stocks Insiders Love Right Now
at The Street - Wed Sep 03, 12:32PM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
SCCO: 27.90 (+0.16), BXS: 22.50 (-0.02), JBHT: 84.91 (-0.02), CSLT: 12.14 (+0.30), KIN: 6.77 (+0.11)
Kindred Biosciences Falls on Disappointing CereKin Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 8:22AM CDT
Shares of Kindred Biosciences, Inc. (KIN) plunged 28.2% as a pivotal field study on its pipeline candidate CereKin (interleukin-1 inhibitor) failed to meet the primary endpoint.
CBPO: 64.79 (-0.59), CBM: 21.62 (+0.37), AMGN: 160.67 (+3.15), KIN: 6.77 (+0.11)
Kindred Biosciences (KIN) in Focus: Stock Tanks 28.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 7:43AM CDT
Kindred Biosciences has seen negative earnings estimate revisions for the current year along with a significant decline in its share price for the past month
CBPO: 64.79 (-0.59), CBM: 21.62 (+0.37), EPZM: 17.71 (+0.01), KIN: 6.77 (+0.11)
Why Kindred Biosciences (KIN) Stock Is Plummeting Today
at The Street - Thu Aug 21, 12:07PM CDT
Kindred Biosciences (KIN) plummeted Thursday after the company announced one of its three lead drug candidates failed to reach its goal in a trial.
KIN: 6.77 (+0.11)
Stock Futures In Positive Mood; Bon Ton Stores Skid Lower
at Investor's Business Daily - Thu Aug 21, 8:09AM CDT
Stock futures stuck to their early gains ahead of Thursday's open, as Europe's markets traded higher and weekly jobless claims data was positive. Dow futures rose 31. 9 points above fair market value. Nasdaq 100 futures notched up 3.6 points and S&P...
MGNX: 33.00 (+0.34), DLTR: 69.86 (-0.20), BONT: 7.52 (+0.40), KIN: 6.77 (+0.11)
KINDRED BIOSCIENCES
at Investor's Business Daily - Wed Aug 20, 5:56PM CDT
KINDRED BIOSCIENCES (KIN) said its CereKin drug to treat pain and inflammation related to osteoarthritis in dogs did not meet goals in a clinical trial. Shares fell 37%.
KIN: 6.77 (+0.11)
Kindred Biosciences Announces Top-Line Results from Pivotal Study of CereKin in Dogs with Osteoarthritis
PR Newswire - Wed Aug 20, 3:01PM CDT
Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that its pivotal field study (KB010) of CereKin, an interleukin-1 inhibitor for the control of pain and inflammation associated with osteoarthritis in dogs, did not meet its primary endpoint. The randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of two doses of CereKin (5 mg/kg and 20 mg/kg).
KIN: 6.77 (+0.11)
